TORONTO--(BUSINESS WIRE)--Paradox Immunotherapeutics (“Paradox”), a pharmaceutical company focused on the development of innovative antibody therapies ... light chain amyloidosis (AL ...

On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ...

J.F. Lehman & Company ("JFLCO"), a leading private equity firm specializing in the aerospace, defense, government, maritime, environmental and infrastructure sectors, is pleased to announce that an ...

A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

On March 17, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease ...

Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from COVID-19 and influenza and broader immunity to different flu strains.

As with all food allergies, a coconut allergy is characterized by an abnormal immune response and the release of an antibody called immunoglobulin E (IgE). The release of IgE sets off a chain reaction ...

Researchers developed a handheld sensor using ECB technology for quick detection of H5N1 influenza in aerosols, enhancing ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...